In this cohort study of 3 544 383 patients with type 2 diabetes in Taiwan, SGLT2is were associated with a significantly lower risk and lower cumulative incidence of sight-threatening retinopathy than dipeptidyl peptidase-4 inhibitors, pioglitazone, and sulfonylureas. Here, DPP4 is linked to type 2 diabetes mellitus.